Literature DB >> 17412540

Early neurological phenotype in 4 children with biallelic PRODH mutations.

Alexandra Afenjar1, Marie-Laure Moutard, Diane Doummar, Agnés Guët, Daniel Rabier, Anne-Isabelle Vermersch, Cyril Mignot, Lydie Burglen, Delphine Heron, Elizabeth Thioulouse, Thierry Billette de Villemeur, Dominique Campion, Diana Rodriguez.   

Abstract

Hyperprolinemia type I (HPI) results from a deficiency of proline oxidase (POX), involved in the first step in the conversion of proline to glutamate. Diverse phenotypes were described in patients with HPI, prior to the identification of the POX gene (PRODH): whereas various patients were asymptomatic, others had neurological and extraneurological defects. The PRODH gene is located in the region deleted in velocardiofacial syndrome (VCFS). Heterozygous and homozygous mutations have been identified in patients with variable hyperprolinemia and various features (patients with schizophrenia, chromosome 22q11 microdeletions and/or neurological defects). A functional study has divided the PRODH missense mutations into three groups: those leading to mild, moderate, or severe reduction of POX activity. In this study, we report four unrelated children with HPI and a homogeneous severe neurological phenotype. We identified biallelic abnormalities in PRODH in these patients that led to severe reduction of POX activity. These included missense and non-sense mutations, deletions of PRODH and a 22q11 microdeletion. Four other children have been reported with severe biallelic PRODH mutations. The phenotype of these eight patients associates early psychomotor development delay with predominant cognitive defects, autistic features and epilepsy. Their values of hyperprolinemia ranged from 400 to 2200 micromol/L. Patients with biallelic PRODH alterations resulting in severely impaired POX activity had an early onset and severe neurological features. Thus, children with this phenotype and those with a microdeletion in chromosome 22q11, especially those with mental retardation and autistic features, should be tested for hyperprolinemia. Hyperprolinemic patients should be screened for PRODH mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412540     DOI: 10.1016/j.braindev.2007.01.008

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  9 in total

1.  Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2.

Authors:  Tingwei Guo; Alexander Diacou; Hiroko Nomaru; Donna M McDonald-McGinn; Matthew Hestand; Wolfram Demaerel; Liangtian Zhang; Yingjie Zhao; Francisco Ujueta; Jidong Shan; Cristina Montagna; Deyou Zheng; Terrence B Crowley; Leila Kushan-Wells; Carrie E Bearden; Wendy R Kates; Doron Gothelf; Maude Schneider; Stephan Eliez; Jeroen Breckpot; Ann Swillen; Jacob Vorstman; Elaine Zackai; Felipe Benavides Gonzalez; Gabriela M Repetto; Beverly S Emanuel; Anne S Bassett; Joris R Vermeesch; Christian R Marshall; Bernice E Morrow
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

2.  Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome.

Authors:  Catherine L Clelland; Laura L Read; Amanda N Baraldi; Corinne P Bart; Carrie A Pappas; Laura J Panek; Robert H Nadrich; James D Clelland
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

Review 3.  Physical manifestations of neurodevelopmental disruption: are minor physical anomalies part of the syndrome of schizophrenia?

Authors:  Michael T Compton; Elaine F Walker
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

Review 4.  Molecular genetics of 22q11.2 deletion syndrome.

Authors:  Bernice E Morrow; Donna M McDonald-McGinn; Beverly S Emanuel; Joris R Vermeesch; Peter J Scambler
Journal:  Am J Med Genet A       Date:  2018-10       Impact factor: 2.802

5.  Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function.

Authors:  Lucas Kempf; Kristin K Nicodemus; Bhaskar Kolachana; Radhakrishna Vakkalanka; Beth A Verchinski; Michael F Egan; Richard E Straub; Venkata A Mattay; Joseph H Callicott; Daniel R Weinberger; Andreas Meyer-Lindenberg
Journal:  PLoS Genet       Date:  2008-11-07       Impact factor: 5.917

Review 6.  In the line-up: deleted genes associated with DiGeorge/22q11.2 deletion syndrome: are they all suspects?

Authors:  Zahra Motahari; Sally Ann Moody; Thomas Michael Maynard; Anthony-Samuel LaMantia
Journal:  J Neurodev Disord       Date:  2019-06-07       Impact factor: 4.025

7.  Hyperprolinemia type I caused by homozygous p.T466M mutation in PRODH.

Authors:  Rina Hama; Jun Kido; Keishin Sugawara; Toshiro Nakamura; Kimitoshi Nakamura
Journal:  Hum Genome Var       Date:  2021-07-20

8.  Mecp2-null mice provide new neuronal targets for Rett syndrome.

Authors:  Rocio G Urdinguio; Lidia Lopez-Serra; Pilar Lopez-Nieva; Miguel Alaminos; Ramon Diaz-Uriarte; Agustin F Fernandez; Manel Esteller
Journal:  PLoS One       Date:  2008-11-07       Impact factor: 3.240

9.  Biochemical and clinical features of hereditary hyperprolinemia.

Authors:  Hiroshi Mitsubuchi; Kimitoshi Nakamura; Shirou Matsumoto; Fumio Endo
Journal:  Pediatr Int       Date:  2014-08       Impact factor: 1.524

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.